# ERA 223 (NCT02043678)

> Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02043678
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Prostatic Neoplasms
- Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Matching placebo (normal saline); Abiraterone; Prednisone/Prednisolone
- Enrollment: 806
- Primary outcome: Symptomatic Skeletal Event Free Survival (SSE-FS)

## Commentary we found

- YouTube: 28
- Podcasts: 20
- X threads: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=era-223-nct02043678

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02043678", "email": "<work email>"}; the inbox owner confirms by the emailed link.